FDA Delays Approval of Alzheimer’s Drug Amid Bipartisan Criticism Over Lobbying Influence

In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has once again delayed the approval of a promising Alzheimer’s drug, sparking widespread debate and bipartisan criticism over the influence of lobbying in the decision-making process. The drug in question, donanemab, developed by pharmaceutical giant Eli Lilly, has been hailed as a potential breakthrough for slowing the progression of Alzheimer’s disease, a devastating condition affecting nearly 7 million Americans, mostly older adults. However, concerns over safety, efficacy, and the role of industry lobbying have led to growing scrutiny of the FDA’s actions.

Background on Donanemab and Its Promise

Donanemab, marketed under the brand name Kisunla, is a monoclonal antibody designed to target amyloid plaques in the brain, a hallmark of Alzheimer’s disease. These plaques are sticky protein deposits believed to contribute to cognitive decline. Clinical trials conducted by Eli Lilly showed that donanemab could slow cognitive and functional decline by up to 35% over 18 months in patients with early symptomatic Alzheimer’s, offering hope to those in the mild cognitive impairment or mild dementia stages. The drug’s unique approach allows treatment to be stopped once amyloid plaques are sufficiently reduced, potentially lowering costs and reducing the need for frequent infusions. FDA Approves Eli Lilly Alzheimer’s Drug

The Alzheimer’s Association estimates that 7.2 million Americans over 65 are living with the condition, a number projected to nearly double by 2060. With such a significant public health challenge, the development of effective therapies is a top priority for patients, families, and healthcare providers. New Alzheimer’s Test Approved by FDA

FDA’s Unexpected Delay

In March 2024, the FDA made a surprising decision to delay the approval of donanemab, opting to convene an advisory committee to further evaluate its safety and effectiveness. This move caught many by surprise, as experts had anticipated a smoother path to approval following promising Phase 3 trial results published in May 2023. The FDA cited the need for additional scrutiny, particularly regarding the drug’s safety profile, which includes risks of brain swelling and bleeding, known as amyloid-related imaging abnormalities (ARIA). While these side effects were reported as mild in most cases, three deaths during clinical trials were linked to the drug, raising red flags. FDA Approves Alzheimer’s Drug Donanemab

The delay was not the first hurdle for donanemab. In 2023, the FDA had initially rejected the drug, citing insufficient data. The subsequent delay in March 2024 further frustrated stakeholders, including patient advocacy groups like the Alzheimer’s Association, which called the decision a setback for those awaiting new treatment options. “A future with more approved Alzheimer’s treatments is a tremendous advancement for people eligible for these drugs,” said Dr. Joanne Pike, president and CEO of the Alzheimer’s Association, emphasizing the urgency of accessible therapies.

Bipartisan Criticism and Lobbying Concerns

The FDA’s decision has drawn bipartisan criticism, with lawmakers from both sides of the aisle questioning whether lobbying efforts by pharmaceutical companies and advocacy groups have unduly influenced the regulatory process. Alzheimer’s drug development has long been a contentious area, marked by high stakes and significant financial interests. The approval of previous Alzheimer’s drugs, such as Aduhelm in 2021, was mired in controversy due to concerns over efficacy and the FDA’s handling of the process, which some critics argued was swayed by industry pressure.

In the case of donanemab, critics point to the extensive lobbying efforts by Eli Lilly and patient advocacy groups, which have pushed for faster approvals to address the unmet needs of Alzheimer’s patients. According to reports, the pharmaceutical industry spent over $300 million on lobbying in 2023 alone, with companies like Eli Lilly investing heavily to influence healthcare policy. Bipartisan lawmakers, including members of the House Energy and Commerce Committee, have called for greater transparency in how the FDA evaluates drugs, particularly when lobbying efforts appear to blur the lines between patient advocacy and corporate interests.

Republican lawmakers have expressed concerns that the FDA’s delays may reflect an overly cautious approach, potentially stifling innovation and denying patients access to life-changing treatments. Meanwhile, Democratic critics argue that the agency must resist pressure from industry giants to ensure rigorous safety standards. “The FDA must prioritize patient safety over corporate profits,” said Representative Anna Eshoo (D-CA), a vocal advocate for healthcare reform. “We need to ensure that lobbying doesn’t overshadow science.”

The Role of Lobbying in Drug Approvals

The influence of lobbying in FDA decisions is not a new issue. The approval of Aduhelm, developed by Biogen and Eisai, sparked significant controversy in 2021 when the FDA granted accelerated approval despite a negative recommendation from its advisory panel. Critics argued that the decision was influenced by close ties between the FDA and Biogen, as well as pressure from advocacy groups. Aduhelm’s commercial failure and eventual discontinuation in 2024 further fueled skepticism about the FDA’s decision-making process.

The donanemab delay has reignited these concerns, with some lawmakers calling for reforms to limit the impact of lobbying on regulatory decisions. Proposals include stricter disclosure requirements for interactions between FDA officials and industry representatives, as well as increased funding for independent research to evaluate drug safety and efficacy. “The American people deserve an FDA that operates with impartiality and transparency,” said Senator Mike Braun (R-IN), who has pushed for greater accountability in the agency.

Impact on Patients and Families

For Alzheimer’s patients and their families, the delay in donanemab’s approval is a source of frustration and disappointment. The disease places a heavy burden on caregivers, with over 11 million unpaid caregivers providing an estimated 18 billion hours of care in 2022, according to the Alzheimer’s Association. Treatments like donanemab offer hope for slowing disease progression, allowing patients to maintain independence and quality of life for longer.

Dr. Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, emphasized the importance of early intervention. “Today’s approval is a transformative moment for patients, clinicians, and the field,” he said, referring to the potential of new diagnostics and treatments like donanemab. However, with the FDA’s delay, patients must wait longer for access to this therapy, potentially missing a critical window for effective treatment.

Looking Ahead

Despite the delay, donanemab’s prospects remain strong. On June 10, 2024, an FDA advisory committee unanimously voted in favor of the drug, concluding that its benefits outweigh its risks for patients with early Alzheimer’s. The FDA typically follows its advisory panel’s recommendations, and the drug was ultimately approved on July 2, 2024, under the brand name Kisunla. However, the earlier delays have left lingering questions about the FDA’s processes and the role of lobbying in shaping outcomes.

As the Alzheimer’s treatment landscape evolves, the focus remains on balancing innovation with safety. The recent approval of a groundbreaking blood test for Alzheimer’s diagnosis, the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marks a step forward in making diagnosis more accessible and less invasive. This test, approved on May 16, 2025, could complement treatments like donanemab by identifying patients at high risk earlier, enabling timely intervention. Statement from the Alzheimer’s Drug Discovery Foundation

The debate over donanemab’s approval underscores the complexities of addressing a public health crisis like Alzheimer’s. While the drug offers hope for millions, the FDA’s cautious approach reflects the need to protect patients from potential risks. As lawmakers, advocates, and industry leaders continue to navigate these challenges, the call for transparency and accountability in the drug approval process grows louder.

For now, patients and families await further developments, hopeful that new treatments will soon provide relief in the fight against Alzheimer’s. The FDA’s decisions in the coming months will be closely watched, as they could set a precedent for how the agency balances innovation, safety, and external pressures in the years ahead.

Also Read :- Apple Faces 25% Tariff Pressure as Trump Urges Reshoring iPhone Production